title: Association between plasma oxidized low-density lipoprotein and diabetic nephropathy.
abstract: To investigate the association of oxidized low-density lipoprotein (ox-LDL) with the development of diabetic nephropathy, plasma levels of ox-LDL were measured in 70 patients with type 2 diabetes mellitus. A sandwich enzyme-linked immunoadsorbent assay (ELISA) using the mouse monoclonal antibody FOH1a/DLH3, which specifically recognizes oxidized phosphatidylcholine, and a horseradish peroxidase (HRP)-labeled goat anti-human apolipoprotein B IgG was used to measure ox-LDL levels. The mean age of the patients was 57.0+/-1 3.4 years, and the mean duration of diabetes was 13.4+/-8.5 years. Plasma ox-LDL levels were similar in patients with normoalbuminuria (13.7+/-3.9 U/ml), patients with microalbuminuria (12.8+/-3.9 U/ml), and normal controls (12.5+/-4.2 U/ml). However, the plasma ox-LDL level in patients with macroalbuminuria (16.8+/-7.5 U/ml) was significantly higher than those in the other groups (P<0.05). Hemoglobin A1c (HbA1c) levels were similar in diabetic patients with normoalbuminuria (8.2+/-2.2%), microalbuminuria (7.8+/-1.3%), or macroalbuminuria (7.2+/-1.4%). There was no significant correlation between the ox-LDL level and the HbA1c level. The significantly elevated plasma ox-LDL levels in patients with macroalbuminuria suggest that ox-LDL may play an important role in the progression of diabetic nephropathy.
authors.affiliation: Diabetes Center and Institute of Geriatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. norikou@pb3.so-net.ne.jp
authors.forename: Noriko
authors.initials: N
authors.lastname: Ujihara
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Sakka
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takeda
authors.forename: Michiyo
authors.initials: M
authors.lastname: Hirayama
authors.forename: Akiko
authors.initials: A
authors.lastname: Ishii
authors.forename: Osamu
authors.initials: O
authors.lastname: Tomonaga
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Babazono
authors.forename: Chieko
authors.initials: C
authors.lastname: Takahashi
authors.forename: Katsuko
authors.initials: K
authors.lastname: Yamashita
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Iwamoto
mesh_terms: D017668:Age of Onset; D000419:Albuminuria / Q000097:blood; D000818:Animals; D000911:Antibodies, Monoclonal; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D051379:Mice; D008875:Middle Aged; D012016:Reference Values
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D007074:Immunoglobulin G; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein